Navigation Links
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Date:12/18/2007

European regulatory authorities support filing strategy

SEATTLE, Dec. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) reported today that it met with and received feedback from the rapporteur and co-rapporteur regarding its marketing authorization application (MAA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103). The feedback supports submission of the MAA in the first quarter of 2008, earlier than the first half of 2008 that CTI was targeting. The rapporteur and co-rapporteur, who are assigned by the EMEA, are responsible for providing scientific advice on the evaluation of medicinal products. CTI plans to submit an MAA in Europe, based on the STELLAR 4 phase III clinical trial results, for XYOTAX as a single agent for first-line treatment of non-small cell lung cancer (NSCLC) in patients with poor performance status (ECOG performance status 2, PS2).

"The meetings were very productive and we appreciate the advice the rapporteurs provided us on how best to report our data and supporting literature for the utility of the comparator drugs gemcitabine and vinorelbine," said Scott C. Stromatt, M.D., Executive Vice President, Clinical Development and Regulatory Affairs. "Based on their feedback and agreement on several critical components of the application, we believe we will be in a position to submit our MAA in the first quarter, months ahead of our previous target."

Lung cancer remains the biggest cancer killer in Europe. The incidence of lung cancer in Europe is more than 13 percent of all cancers, and in 2000 resulted in nearly 350,000 deaths.

About PS2 NSC Lung Cancer

PS2 patients represent a subgroup of patients who are ambulatory and capable of self-care, but are unable to carry out any work activities, although they are up and about more than 50 percent of waking hours. PS2 non-small cell lung cancer (NSCLC) patients account for approximately 25 percent of all patients with NSCLC
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015  The University of California, San ... and UC San Diego Extension announced their third ... Aug.  12 – 14, 2015, at UC San ... provides an intense exposure to best practices and ... well-suited to biologists, process engineers and business executives ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... first participant in its Phase 1/2 clinical trial ... chronic unilateral Achilles tendinosis, has been enrolled and ... intra-tendon ultrasound-guided injections. RCT-01 is comprised of non-bulbar ...
(Date:6/30/2015)... ... June 30, 2015 , ... Southern ... accepted the position of vice president of instruction at Chippewa Valley Technical College ... greatly appreciated the opportunity to lead SIUE during the past three years,” Furst-Bowe ...
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... announced today the availability of the world,s first clinical guidelines to ... cells to treat disease. , ... Broomfield, CO (PRWEB) ... ASCTA ) announced today the availability of the world,s first clinical ...
... illustrate potential cost effective approach for, ... Symbol: RVX,CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - ... pleased to announce today that it has made ... (R&D) program for inflammatory diseases. Two new patent ...
... Therapeutic for IBD with Novel Mode of ActionMOUNTAIN ... Inc., today announced that data from the company,s ... Crohn,s disease Trial) Phase II/III clinical trial of ... will be presented in an oral session at ...
Cached Biology Technology:Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 2Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 3Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 4Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 2Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
(Date:6/15/2015)... According to a new market ... Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & ... MarketsandMarkets, The Natural Language Processing Market is expected to ... for the forecast period 2015-2020. Browse ... igures spread   through 155 P ages and ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... are working to improve understanding about obesity and cancer. ... Applied Physiology, Nutrition, and Metabolism , is the first ... than estimates like body mass index (BMI) or waist ... cancer risk in aging populations. Findings emphasize the negative ...
... publishes "Assessing Dangerous Climate Change: Required Reductions of Carbon ... from James Hansen and colleagues, and announces call for ... Research article assesses climate impacts of global warming using ... energy imbalance and simple representations of the global carbon ...
... edges of most public forests in Oregon and Washington more ... the U.S. Forest Service Pacific,s Northwest (PNW) Research Station has ... structures at the fringes of public forests, is the first ... and after the enactment of land use laws. The findings ...
Cached Biology News:Radiographic imaging exposes relationship between obesity and cancer 2Assessing dangerous climate change and call for climate change response papers 2Development near Oregon, Washington public forests 2
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... Blocker Array II can be used to ... various proteins and sera that are commonly ... The array contains spots for 19 different ... Determination of antibody crossreactivity and species specificity, ...
... sufficient materials for 1,464 array sample elements. , ... , Blocker BSA in PBS (10X): 50 ... 10 g , BupH Phosphate Buffered ... 2 x 10 ml ampules , SuperSignal West ...
Biology Products: